Precision BioSciences (DTIL)
(Real Time Quote from BATS)
$9.94 USD
-0.28 (-2.74%)
Updated Sep 18, 2024 02:46 PM ET
1-Strong Buy of 5 1
B Value C Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DTIL 9.94 -0.28(-2.74%)
Will DTIL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
Other News for DTIL
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
Precision BioSciences chief medical officer Alan List to retire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
Precision BioSciences Secures Funds, Bolsters Oncology Partnership
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal